Few new drugs deserve expedited regulatory treatment
- PMID: 33908278
- PMCID: PMC10390900
- DOI: 10.18553/jmcp.2021.27.5.685
Few new drugs deserve expedited regulatory treatment
Abstract
DISCLOSURES: This commentary is based on work by the author that was supported by Arnold Ventures and the Harvard-MIT Center for Regulatory Science. The funders had no role in the writing of this commentary, or the decision to submit for publication. The author has nothing else to disclose.
Conflict of interest statement
This commentary is based on work by the author that was supported by Arnold Ventures and the Harvard-MIT Center for Regulatory Science. The funders had no role in the writing of this commentary, or the decision to submit for publication. The author has nothing else to disclose.
Comment in
-
Simplify drug labelling to show benefits clearly.Nature. 2021 Nov;599(7884):181. doi: 10.1038/d41586-021-03050-z. Nature. 2021. PMID: 34754092 No abstract available.
References
-
- Darrow JJ, Avorn J, Kesselheim AS. Speed, safety, and industry funding: from PDUFA I to PDUFA VI. N Engl J Med. 2017;377(23):2278-86. - PubMed
-
- Darrow JJ. Pharmaceutical efficacy: the illusory legal standard. Wash. & Lee L. Rev. 2013;70:2073-136.
-
- HR Rep No. 97-840(I) (1982), reprinted in 1982 U.S.C.C.A.N. 3577.
-
- Investigational new drug, antibiotic, and biological drug product regulations; procedures for drugs intended to treat life-threatening and severely debilitating illnesses. Fed Regist. 1988;53(204):41516-24.
-
- US Food and Drug Administration. Medical review (eteplirsen, 206488Orig1s000). July 20, 2016. Accessed April 13, 2021. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/206488orig1s000m...
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources